Effect of early glycemic control on HbA1c tracking and development of vascular complications after 5 years of childhood onset type 1 diabetes: Systematic review and meta-analysis

Veena Mazarello Paes1,2 | Jessica K. Barrett3 | David C. Taylor-Robinson4 | Heather Chesters1 | Dimitrios Charalampopoulos1 | David B. Dunger2,5 | Russell M. Viner6 | Terence J. Stephenson1

1Great Ormond Street Institute of Child Health, University College London, London, UK
2Department of Paediatrics, University of Cambridge, Cambridge, UK
3MRC Biostatistics Unit, University of Cambridge, Cambridge, UK
4Institute of Population Health Sciences, University of Liverpool, Liverpool, UK
5Wellcome Trust/MRC Institute of Metabolic Sciences, University of Cambridge, Cambridge, UK
6The Royal College of Paediatrics and Child Health, London, UK

Correspondence
Veena Mazarello Paes, UCL Great Ormond Street Institute of Child Health, 1 floor, Wellcome Trust Building, 30 Guilford Street, London WC1N 1EH, UK. Email: veena.paes.14@ucl.ac.uk

Funding information
The Department of Health and Social Care, Grant/Award Number: 109/0001

Abstract
Objective: A systematic review and meta-analysis was conducted to investigate if glycemic control measured by glycated hemoglobin (HbA1c) levels near diagnosis are predictive of future glycemic outcomes and vascular complications in childhood onset type 1 diabetes (T1D).

Methods: Evidence was gathered using electronic databases (MEDLINE, EMBASE, Web of Science, CINAHL, Scopus, and Cochrane Library up to February 2017) and snowballing techniques. Studies investigating the association between the exposure “early glycemic control” and main outcome: “tracking of early control” and secondary outcome: risk of future complications; in children and young people aged 0 to 19 years at baseline; were systematically double-reviewed, quality assessed, and outcome data extracted for synthesis and meta-analysis.

Findings: Five studies (N = 4227 participants) were eligible. HbA1c levels were sub-optimal throughout the study period but tended to stabilize in a “track” by 6 months after T1D diagnosis. The group with low HbA1c <53 mmol/mol (<7%) at baseline had lower long-term HbA1c levels than the higher HbA1c group. The estimated standardized mean difference between the sub groups showed a reduction of HbA1c levels on average by 1.6% (range −0.95% to −2.28%) from baseline. Only one study investigated the association between early glycemic control and development of vascular complications in childhood onset T1D.

Interpretations: Glycemic control after the first few months of childhood onset T1D, remains stable but sub-optimal for a decade. The low and high HbA1c levels at
baseline seem to “track” in their respective tracks during the 10-year follow-up, however, the initial difference between groups narrows over time.

PROSPERO: CRD42015024546 http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015024546

KEYWORDS
childhood-onset, complications, glycemic control, risk, T1D

1 | INTRODUCTION

Glycated hemoglobin (HbA1c) levels, a measure for glycemic control is the main predictor of long-term type 1 diabetes (T1D) outcomes. HbA1c levels are highest at diagnosis, but improve after insulin treatment and remain stable in most T1D patients. However, a few find it challenging to maintain good glycemic control despite targeted or intensive interventions, as they go through various stages in life.

Studies mainly in adults have shown a link between poor glycemic control in the early phase following T1D diagnosis and long-term HbA1c levels, with an increased risk of developing vascular complications and mortality. The risk of vascular complications is likely to be greater for childhood onset T1D, because of a longer duration of glycemic exposure and pathophysiological factors, such as reduced insulin sensitivity and psychosocial behaviors, such as insulin omission. For childhood onset T1D, some observational studies indicate an association between poor glycemic control within 1 or 2 years of diagnosis and vascular complications in later life.

Others suggest that mean HbA1c levels nearer to diagnosis are predictive of HbA1c levels in the subsequent years, even lifetime, regardless of the type of insulin regimen. This phenomenon, also known as glycemic “tracking,” is poorly understood. It is unclear exactly when and in whom the phenomenon of “tracking” of HbA1c occurs in childhood onset T1D and if it is because of the natural history of T1D. It is therefore important to investigate the evidence on this phenomenon to identify if there exists a window period in the initial phase of T1D diagnosis, during which appropriate resources could be mobilized to deliver targeted interventions to those at risk of developing poorer long-term glycemic outcomes and vascular complications.

The purpose of our study was to carry out a systematic review and meta-analysis of the evidence assessing the impact of early glycemic control in children (followed for at least 5 years from diagnosis) on tracking of early control and the risk of developing vascular complications.

2 | METHODS

This review is part of a series of systematic reviews of evidence on the effects of early glycemic control in childhood onset T1D. The review protocol was registered in PROSPERO (Registration number: CRD42015024546) and a detailed protocol published. We followed the review methods for the rigorous conduct and reporting of systematic reviews for policy and practice as described by the Evidence for Policy and Practice Information (EPPI) Centre which are as per PRISMA guidelines.

2.1 | Search strategy

A refined search strategy was designed after a number of initial iterative scoping searches, with input from experts in the field to maximize capturing of key publications. Three sets of search terms were used relating to population (children and young people diagnosed with T1D), exposure (terms to capture observational, intervention, qualitative studies, and review articles relating to early diabetes control) and outcome (complications, mortality, glycemic tracking i.e., metabolic memory) (Additional File 1).

Six electronic databases: (MEDLINE and EMBASE through OVID, Web of Science through Thompson Reuters, CINAHL Plus through EBSCO, Scopus through Elsevier, and the Cochrane Library), were double searched in parallel by HC & VMP from inception to December 2014 and updated in February 2017 by using a combination of free text and Thesaurus or MeSH terms (Additional File 2). No time-period or language restrictions were applied. All identified articles from electronic databases were imported into Endnote and de-duplicated for further review. This was supplemented by hand-searching of reference lists of studies and reviews, gray literature, personal databases and contacting experts and authors of included studies for additional or unpublished data.

2.2 | Study selection

Interventional and observational studies with a follow-up of ≥5 years from diagnosis of T1D which described and quantified the association between early glycemic control (defined as glycemic control within 2 years of diagnosis of T1D) AND long-term glycemic tracking (defined as settling of HbA1c levels into long-term tracks of either > or <7% ie, 53 mmol/mol) and risk of future complications in children and young people aged 0 to 19 years at baseline were included (Additional File 3).

In addition to running electronic database searches in parallel (HC and VMP), sub-samples of papers were double-reviewed (DC and VMP), at each stage of the review process (title and abstract screening, data extraction and quality assessment). The interrater reliability
for study selection was substantial.22 Full texts of abstracts appearing to meet the inclusion criteria were retrieved and their status was recorded in a pre-piloted excel spreadsheet, which included specific study details and reasons for exclusion (for excluded studies). No foreign language papers were identified. Articles were re-examined (DC and VMP) if there was uncertainty about inclusion criteria and disagreements were resolved at team meetings.

2.3 | Data extraction

Data from included studies were extracted, analyzed, and synthesized by one reviewer (VMP). A proportion of shortlisted studies were also independently double reviewed and data extracted (DC and RA). From observational studies, data on HbA1c levels were extracted at all available time points from diagnosis. Data on HbA1c tracking and the association between early glycemic control and chronic complications or markers of chronic complications at follow-up were extracted (Additional File 4). Authors of included studies were contacted for clarity and additional information on HbA1c tracking data where necessary. The main outcome of interest was tracking of early glycemic control based on HbA1c measurements as percentage (DCCT) and/or mmol/mol (International Federation of Clinical Chemistry) units. The secondary outcome of interest was the impact of early glycemic control on the development of micro and macro vascular complications during the long-term follow-up period.

2.4 | Quality assessment

The quality of included studies was assessed independently by two reviewers (DC and VMP) using the quality assessment criteria by the EPPI Centre.20 Any disagreements were resolved by consensus. Scores were based on six items focusing on both internal and external validity (Additional File 5). Observational studies were classified as high (>5), intermediate3,4 or low (≤2) quality based on the number of quality criteria met out of a maximum assessment score of six.

2.5 | Statistical analysis

Information extracted from included studies were summarized through descriptive narrative synthesis and meta-analysis.23 All statistical analyses were conducted by one reviewer (VMP) and were verified by a second reviewer (JB). The sample size, mean HbA1c measurements and SD or SE were available at population level and/or for categorized low and high HbA1c groups. Where not reported, the SE of the study at each time point was calculated using the reported SD and the group sample sizes. Baseline period included 3 to 6 months from T1D diagnosis. Mean HbA1c levels at diagnosis was not included in the main meta-analysis as by definition they were measured prior to exposure of glycemic control with insulin therapy. The effect sizes and their SE were divided with SD to obtain standardized mean differences (SMD).24

The primary outcome was the population mean HbA1c level at baseline (0, 3, and 6 months of diagnosis), 1, 2, 3, 5, 7, and 10 years follow-up. A further primary outcome was the difference in HbA1c levels between the low HbA1c (<7% at baseline) group (considered the “treated/exposed” group) and the high HbA1c group (≥7% at baseline) (the “control” group), reported as standardized mean differences. If multiple measurements of HbA1c were reported at follow-up then these measures were combined within each study before meta-analysis. Heterogeneity between studies was expected and therefore both fixed effects (FE, inverse variance) and random effects (RE, DerSimonian, and Laird) models were used to pool the effect sizes and reported using forest plots.25 The heterogeneity between studies was assessed using the $I^2$ test for heterogeneity and $I^2$ statistics.26 The meta-analyses were carried using the meta command in STATA 15, StataCorp, College Station, Texas.

For glycated hemoglobin, the estimated pooled standardized mean differences were converted into absolute units, to facilitate clinical interpretation, by multiplying the estimate by the pooled SD of all included studies of the meta-analysis.

Furthermore, the long-term population average HbA1c trajectory from each study was plotted alongside the overall estimate at all-time points of follow-up obtained from the meta-analysis. The trajectories of HbA1c sub groups (low v/s high) in each study were also plotted.

The robustness of the meta-analysis to the choice of meta-analysis model was assessed by comparing FE and RE pooled standardized effect sizes. In a sensitivity analysis we excluded studies in pre-school children.

Assessing publication bias using the funnel plots, the Begg’s rank correlation test or the Egger’s linear regression test was deemed inappropriate as there were insufficient studies included in the review.

Because of the small number of included studies, meta-regression was not appropriate to explore heterogeneity between studies or to investigate if there were other potential factors that could be independently associated with long-term glycemic control. A minimum of 10 studies per study level parameter would be needed for meta-regression.

Only one included study assessed the association of micro and macro-vascular complications with early glycemic control, which precluded a meta-analysis and results of which were narrated separately.

3 | RESULTS

The literature search strategy on glycemic control in childhood onset T1D identified articles from individual databases (Medline through OVID, n = 14 688; Embase through OVID, n = 843; Web of Science through Thompson Reuters, n = 2734; CINAHL Plus through EBSCO, n = 1185; Scopus through Elsevier, n = 2837 and Cochrane library, n = 4052). After de-duplication 21 063 articles were screened, out of which 390 were shortlisted for full review (Figure 1). There was good agreement between reviewers on identifying abstracts for full text review. A total of 385 studies were excluded from the systematic review and meta-analysis for reasons shown in Figure 1. Five fairly recent studies24,27–30 conducted in developed countries (Israel, Scotland, Sweden, and USA) with a total of 4227 participants met the
inclusion criteria of the systematic review. The studies investigated national,24 regional,27 Children's hospital,29 academic medical centre30 and clinic28 level data.

3.1 | Characteristics of included studies

The Swedish cohort study24 consisted of 1543 children and adolescents (920 males) from two nationwide population-based Swedish registries (Swedish Pediatric Quality Registry and Swedish National Diabetes Register) covering a period from year 2000 to 2010. The mean age at diagnosis was 13.9 (range 5.0-19.0) years and the mean follow-up was for 7.1 ± 2.5 (range 1.0-12.0) years. The study investigated whether high mean HbA1c values 3 to 15 months after diagnosis of T1D in childhood was associated with future glycemic control, albuminuria and retinopathy in early adulthood.

The American study29 prospectively investigated, between the years 1993 and 2009, whether age at diagnosis, gender, ethnicity, diagnostic era (year of diagnosis) and type of insulin therapy were associated with tracking of glycemic control at 5 years follow-up post diagnosis of T1D. A total of 2218 (1166 males) mainly non-Hispanic Caucasian (86.1%) children and adolescents participants with a mean age of 9.0 ± 4.1 years at diagnosis (range 0-20 years), were identified from the Children's Mercy Hospital T1Ds in pediatrics database, USA. Insulin therapy (split regimen dosing, multiple daily injections and continuous subcutaneous insulin infusion) and diagnostic methods used to analyze HbA1c varied during the study period. Information on the socio-economic status and T1D history in family was not reported.

The Israeli study28 was a retrospective observational study, investigating HbA1c tracking in 173 mainly Jewish (84.4%) preschool aged children (84 males) aged 0.5 to 6.5 years at diagnosis between 1993 and 2009 at a tertiary level diabetes clinic in Israel, with a median T1D duration of 4.3 years (range 1 to 11 years) and followed up for 7 years from T1D onset. All patients were advised on carbohydrate counting, required to perform >6 self- blood glucose measurements per day and both multiple daily injections and insulin pumps were used.

Further details of the data extracted from the five studies included in the systematic review are in Table 1.

3.2 | Study quality

The quality of the observational studies was intermediate to high. Two studies were assessed to be “high” quality with a score of five each24,29 and the other three were of “intermediate” quality, with scores of four27,30 and three28 out of a possible score of six respectively. No studies included in the review were of low quality.
| Author, year, country and study period | Study design and data source | Population | Age range of study population | Follow-up period | Treatment | Outcome and measure | Definition of early HbA1c | Statistical Analyses | Association | Quality score (max 6) and comments |
|---------------------------------------|-------------------------------|------------|-------------------------------|-------------------|-----------|-------------------|--------------------------|-----------------|-----------------|-----------------------------|
| Samuelsson 2014<sup>24</sup> Sweden 2000 - 2010 | Retrospective/Prospective pilot study Swedish paediatric diabetes quality registry (SWEDIABKIDS) and the national diabetes register (NDR). | Generalizability: Non rep Sample size: 1543 children and adolescents. Sexes: 920 Ethnicity: NR SES: NR Family history of T1D: NR 5-9 yr olds: N= 89 (5.8%) 10-14 yr olds: N= 769 (49.8%) 15-19 yr olds: N= 685 (44.4%) | Mean visits in SWE: 19.5 Mean visits in NDR: 4 Mean age in SWE: 13.9±2.5 years Mean age in NDR: 21.0±2.3 years | 5-19 years Mean age at diagnosis: 13.9±2.5 years. 1-12 years Mean: 7.1 ±2.5 years | NR | Metabolic control (HbA1c) and detection of albuminuria, retinopathy in early adulthood Standardised assay for HbA1c. Urine albumin excretion. Physical activity levels | HbA1c values between 3 and 15 15 months after diagnosis | 1) MVLR: Mean HbA1c in NDR (dependent) and Mean HbA1c months 3-15 after diagnosis (independent: a) Unadjusted: R-square 0.159, Beta Coefficient 0.466; 95% CI (0.408 – 0.529); t=15.6; p<0.001 b) Adjusted (for age at diagnosis, gender, duration of diabetes, smoking PA): R-square 0.206, Beta Coefficient 0.414; 95% CI (0.355 – 0.473); t=13.2; p<0.001 2) LR unadjusted OR with 95% CI a) HbA1c group 6.8 – 8.6% (51.69 mmol/mol); Ref ≤ 6.7% (≤50 mmol/mol): i) Macroalbuminuria: 1.3 (0.3 – 6.0) ii) Microalbuminuria: 0.9 (0.5 – 1.4) iii) Retinopathy: 1.6 (1.2 – 2.1); p<0.01 b) HbA1c group ≥ 8.7% (>70 mmol/mol); Ref ≤6.7% (<50 mmol/mol): i) Macroalbuminuria: 12.3 (3.2 – 46.8); p<0.01 ii) Microalbuminuria: 2.0 (1.1 – 3.8); p<0.05 iii) Retinopathy: 2.6 (1.7 – 3.8); p<0.01 3) LR adjusted (gender, duration of T1D, age at diagnosis, PA and smoking) OR with 95% CI | ++ Children with poor metabolic control adjacent to diagnosis had higher HbA1c levels in adulthood. ++ micro and macroalbuminuria and retinopathy in early adults seen in patients with high mean HbA1c during 3-15 mo post diagnosis. ++ HbA1c levels higher in young children as compared to pubertal children (12 y for girls and 14 y for boys) + girls had higher HbA1c levels + PA levels lower in patients with high HbA1c levels, micro/macro albuminuria and retinopathy +Smoking observed in patients with high HbA1c levels, micro/macro albuminuria and retinopathy | High [5] non-representative child population. Children < 5 years not included
| Clements 2014 | USA 1993 - 2009 | MAZARELLO PAESET AL.     |
|--------------|-----------------|-------------------------|
| Prospective cohort | The Children's Mercy Hospital Type 1 diabetes in pediatrics database, USA. | Generalizability: Rep |
| Sample size: 2218 children and adolescents. | Males: 1166 | 0-20 years Mean age at diagnosis: 9.0 ±4.1 years |
| Ethnicity: 86.1% non-Hispanic Caucasian, 8.9% non-Hispanic African-American, 5% other or Hispanic, | SES: NR | Stratified by diagnostic era which included the following regimen as first line therapy Pre 2000: Split regimen dosing 2000-2003: multiple daily injections 2004-2009: Continuous subcutaneous insulin infusion |
| Family history of T1D: NR | 5 years | HbA1c during first 3 months of diagnosis and/or 4 – 12 months after diagnosis |
| 1) Association with HbA1c levels at diagnosis, 1.5 and 5 years f/u by diagnostic age, ethnicity, and diagnostic era Various methods used to measure HbA1c during the study period i.e. HPLC, Bioronate affinity. | 2) Effect of insulin therapy on HbA1c tertiles i.e. Children with <7% (<53mmol/L) | Mean (SD) 1st HbA1c after 3 months of diagnosis 7.7 ± 1.9 (60.7 ±20.8 mmol/mol) V/S mean HbA1c in the 5th year after diagnosis 9.2 ± 1.8 (106.6 ±28.0 mmol/mol) |
| Comparison of mean 1st HbA1c after 3 months of diagnosis V/S mean HbA1c in the 5th year after diagnosis by HbA1c tertiles <7, 7-9 and >9% (<53, 53-75 and >75 mmol/mol) (1) HbA1c in children with < 7: mean 6.2 ± 0.5 (n = 871) v/s 9.1 ± 1.8 (n = 609 missing) (2) HbA1c 7 – 9: mean 7.9 ± 0.6 (n = 940) v/s 9.1 ± 1.5 (n=483 missing) (3) HbA1c > 9: mean 10.7 ± 1.8 (n = 407) v/s 9.8 ± 2.0 (n=201 missing) | Regression, stratified analyses Effect of insulin therapy: Children with <7% (53mmol/mol) at diagnosis | ++ Significant increase in HbA1c levels by increasing age of diagnosis with ≥10 year olds experiencing poorer glycaemic control. Younger patients had better control across all HbA1c sub categories p<0.001 |
| The group with HbA1c <7 has steeper increase for the first 1.5 years. However, it seems all three groups ended at about the same level at 5 years except for the patients who were diagnosed at >10 years old of the HbA1c >9 group. | High [5] 5 different methods used to analyse HbA1c during the study period | ++ 0-4 year old did not show much change in HbA1c trajectory over 5 years, but progressive increase in HbA1c levels in all age groups, highest in >10 year olds (p<0.001). Highest HbA1c inflection point is at around 1.5 years post diagnosis ++ Small but statistically significant differences within gender subgroups across diagnostic age groups (p<0.0001). |
| Study | Design | Country | Sample Size | Age | Follow-up | HbA1c | Baseline | HbA1c Trends | LMR | Significance |
|-------|--------|---------|-------------|-----|-----------|-------|----------|-------------|-----|-------------|
| Lawes 2014 | Retrospective cohort | North of Scotland, UK | 155 children ≤ 16 years | 0-16 years | Up to 15 years | 7-9% (53-75 mmol/mol) and >9% (>75%) | had higher HbA1c levels during 1.5 years after diagnosis across all age groups. Overall HbA1c levels rose yearly by 1.83% (1.72 to 1.94) (20.0 mmol/mol (18.8 to 20.2)). HbA1c rise was less steep but significant in children with baseline HbA1c between 7% (53 mmol/mol) and 9% (75 mmol/mol) (0.81% (0.69 to 0.92) (8.9 mmol/mol (7.5 to 10.1))). Patients with baseline HbA1c >9% (75 mmol/mol) had stable or improved control at 1.5 years post diagnosis with an overall yearly decline of -0.68% (-0.87 to -0.49) per year (-7.4 mmol/mol (-9.5 to -5.3)). Non-Hispanic black vs non-Hispanic white mean (SD): 10.2% (±2.5) (88.0 ±27.3 mmol/mol) and 8.4% (±1.4) (68.0 ±15.3 mmol/mol). Pre 2000 era mean (SD): 8.9% (±1.5) (73.8 ±16.4 mmol/mol) 2000-2003 mean (SD): 8.7% (±1.6) (71.6 ±17.5 mmol/mol) 2004-2009 mean (SD): 8.1% (±1.7) (65.0 ±18.6 mmol/mol). ++ Significant mean HbA1c levels and shape of trajectories after adjusting for patient and observation level predictors. ++A higher 6 month HbA1c was associated with slow but sustained HbA1c deterioration with T10 duration as compared to lower 6 month HbA1c. | Lower use of intensive insulin (basal bolus) regimens. No patients | Bayer DCA 2000 near-Intermediate (6) Retrospective study design. Non-rep - excluded patients with < 1 year f/u from diagnosis. Included only |
| Service, ethnic diversity, and family history of T1D | Generalizability: | Population: All patients (n = 6,119) | HbA1c trend (in patients with ≥5% increase in HbA1c) | HbA1c at T1D onset | HbA1c in patients with >75% follow-up | HbA1c in patients with >75% follow-up |
|---|---|---|---|---|---|---|
| Patients from North Scotland, 32% of whom reported living in remote/rural areas. | Retrospective cohort study | 3,115 patients enrolled from diabetes clinic at a tertiary hospital in Israel between January 1999 and May 2009 | In patients with ≥5% increase in HbA1c, HbA1c trend (over 0–17 years) was 0.5% per year. | HbA1c at T1D onset | - | - |
| Mean age at diagnosis: 3.8 ± 1.6 years | Patients with T1D for ≥5 years | HbA1c at T1D onset: 0.5% increase in HbA1c in patients with ≥5% increase in HbA1c. | Age at diagnosis: | HbA1c at T1D onset: 0.5% increase in HbA1c in patients with ≥5% increase in HbA1c. | Age at diagnosis: | HbA1c at T1D onset: 0.5% increase in HbA1c in patients with ≥5% increase in HbA1c. | Age at diagnosis: | HbA1c at T1D onset: 0.5% increase in HbA1c in patients with ≥5% increase in HbA1c. |
| Patients with T1D for ≥5 years | HbA1c at T1D onset: 0.5% increase in HbA1c in patients with ≥5% increase in HbA1c. | Age at diagnosis: | HbA1c at T1D onset: 0.5% increase in HbA1c in patients with ≥5% increase in HbA1c. | Age at diagnosis: | HbA1c at T1D onset: 0.5% increase in HbA1c in patients with ≥5% increase in HbA1c. | Age at diagnosis: | HbA1c at T1D onset: 0.5% increase in HbA1c in patients with ≥5% increase in HbA1c. |
| Patients with T1D for ≥5 years | HbA1c at T1D onset: 0.5% increase in HbA1c in patients with ≥5% increase in HbA1c. | Age at diagnosis: | HbA1c at T1D onset: 0.5% increase in HbA1c in patients with ≥5% increase in HbA1c. | Age at diagnosis: | HbA1c at T1D onset: 0.5% increase in HbA1c in patients with ≥5% increase in HbA1c. | Age at diagnosis: | HbA1c at T1D onset: 0.5% increase in HbA1c in patients with ≥5% increase in HbA1c. |
| Patients with T1D for ≥5 years | HbA1c at T1D onset: 0.5% increase in HbA1c in patients with ≥5% increase in HbA1c. | Age at diagnosis: | HbA1c at T1D onset: 0.5% increase in HbA1c in patients with ≥5% increase in HbA1c. | Age at diagnosis: | HbA1c at T1D onset: 0.5% increase in HbA1c in patients with ≥5% increase in HbA1c. | Age at diagnosis: | HbA1c at T1D onset: 0.5% increase in HbA1c in patients with ≥5% increase in HbA1c. |
| Patients with T1D for ≥5 years | HbA1c at T1D onset: 0.5% increase in HbA1c in patients with ≥5% increase in HbA1c. | Age at diagnosis: | HbA1c at T1D onset: 0.5% increase in HbA1c in patients with ≥5% increase in HbA1c. | Age at diagnosis: | HbA1c at T1D onset: 0.5% increase in HbA1c in patients with ≥5% increase in HbA1c. | Age at diagnosis: | HbA1c at T1D onset: 0.5% increase in HbA1c in patients with ≥5% increase in HbA1c. |
| Patients with T1D for ≥5 years | HbA1c at T1D onset: 0.5% increase in HbA1c in patients with ≥5% increase in HbA1c. | Age at diagnosis: | HbA1c at T1D onset: 0.5% increase in HbA1c in patients with ≥5% increase in HbA1c. | Age at diagnosis: | HbA1c at T1D onset: 0.5% increase in HbA1c in patients with ≥5% increase in HbA1c. | Age at diagnosis: | HbA1c at T1D onset: 0.5% increase in HbA1c in patients with ≥5% increase in HbA1c. |
| Patients with T1D for ≥5 years | HbA1c at T1D onset: 0.5% increase in HbA1c in patients with ≥5% increase in HbA1c. | Age at diagnosis: | HbA1c at T1D onset: 0.5% increase in HbA1c in patients with ≥5% increase in HbA1c. | Age at diagnosis: | HbA1c at T1D onset: 0.5% increase in HbA1c in patients with ≥5% increase in HbA1c. | Age at diagnosis: | HbA1c at T1D onset: 0.5% increase in HbA1c in patients with ≥5% increase in HbA1c. |
| Cabrera et al. 2013 | Retrospective cohort | Generalizability: Rep. Sample size: 138 children 1.1 – 13.9 year old. Males: 71. Ethnicity: white=91.5%, other=8.5%. SES: parental marital status and insurance type reported. Family history of T1D: NR. Mean duration of diabetes: 5 years. | ≥7.5% : n=120 (69.4% patients) At 1 year after onset: 8.4 ±0.9 (n=120) At 2 years after onset: 8.3 ±0.8 (n=98) At 3 years after onset: 8.4 ±0.8 (n=79) At 4 years after onset: 8.4 ±0.8 (n=68) At 5 years after onset: 8.4 ±0.9 (n=57) At 6 years after onset: 8.4 ±0.9 (n=47) At 7 years after onset: 8.3 ±1.0 (n=42) HbA1c at last visit: 8.4±1.0 | At 1 year after onset: 8.4 ±0.9 (n=120) At 2 years after onset: 8.3 ±0.8 (n=98) At 3 years after onset: 8.4 ±0.8 (n=79) At 4 years after onset: 8.4 ±0.8 (n=68) At 5 years after onset: 8.4 ±0.9 (n=57) At 6 years after onset: 8.4 ±0.9 (n=47) At 7 years after onset: 8.3 ±1.0 (n=42) HbA1c at last visit: 8.4±1.0 |
|---|---|---|---|---|
| USA 1998-2002 | Electronic clinical database of the Section of Pediatric Endocrinology /Diabetology at Riley Hospital for Children, Indiana, USA. | Generalizability: Rep. Sample size: 138 children 1.1 – 13.9 year old. Males: 71. Ethnicity: white=91.5%, other=8.5%. SES: parental marital status and insurance type reported. Family history of T1D: NR. Mean duration of diabetes: 5 years. | 1.1 – 13.9 years | 0–5 years | 0–5 years | Patients with initial T1D education from academic medical center (AMC) vs non-AMC patients. Insulin therapy: NR. | HbA1c levels at 0, 2, 3 and 5 years after diagnosis in AMC vs non AMC referred patients. Initial A1C by either by Bayer DCA2000 or by HPLC at the central lab. All patients subsequently had their A1C determined by the Bayer DCA2000 at follow-up clinic visits. A1C levels were obtained from the records of subsequent clinic visits, and mean A1C was calculated for years 2, 3, and 5 from date of diagnosis. | HbA1c at T1D onset | Mean (SE); At diagnosis: 9.53(0.24) GEE Mean(SE): at 2 years: 8.81(0.09) at 3 years: 8.94(0.12) at 5 years: 8.84(0.12) Correlations of A1C values over time for all individual patients (p<0.001) Change from 2 to 3 years (n=130): 0.648 Change from 2 to 5 years (n=130): 0.524 Change from 3 to 5 years (n=138): 0.520 | The A1C was also highly consistent in each patient over time. | "/ Long-term glycaemic control was independent of whether initial education was delivered at an AMC or non-AMC. Formal education and location at time of diagnosis do not appear to play a significant role in long-term glycaemic control. Attrition rate appears to be 8 at 2 and 3 years |

Abbreviations: BMI SDS, body mass index SD score; CI, confidence intervals; GEE, generalized estimating equation; LMR, Linear multilevel regression; LR, logistic regression; MVLR, Multivariate linear regression; NON REP, non representative of general population; MLRA, multiple logistic regression analysis; PA, physical activity; OR, odds ratio; SD/E, standard deviation/error; T1D, type 1 diabetes; ++, statistically significant positive association; + or -, statistically non- significant positive or negative association.
3.3 | Early HbA1c levels and long-term tracking of glycemic control

All five studies included in the review assessed the association between early glycemic control and later HbA1c levels. Population mean HbA1c was available at various follow-up time points (0, 3, 6, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, and 156 months after T1D diagnosis). In addition, four studies provided data on the association between early glycemic control and later HbA1c levels within subgroups of low and high HbA1c identified at baseline.24,27–29

To study the impact of early glycemic control on later HbA1c levels, data from all five studies could be pooled in the review. The number of studies reporting the effect during each time point of the study period varied. All studies reported sub-optimal estimated mean long-term glycemic control at all of the investigated time points during the 10-year follow-up period. The sample size varied from 25 to 2218 and the study periods ranged between years 1993 and 2012. After using the population mean HbA1c and SE in the FE & RE models, the estimated pooled magnitude of the mean HbA1c levels (95% CI) was suboptimal at 11.56% (CI: 11.46, 11.66%) at diagnosis, 7.74% (CI: 7.68, 7.80%) after 3 months 7.61% (CI: 7.47, 7.76%) after 6 months, 7.79% (CI: 7.71, 7.87%) after 1 year, 7.90% (CI: 7.83, 7.98%) after 2 years, 7.94% (CI: 7.86, 8.03%) after 3 years, 8.57% (CI: 8.49, 8.65%) after 5 years, 7.99% (CI: 7.85, 8.12%) after 7 years and 8.59% (CI: 8.24, 8.94%) after 10 years of T1D diagnosis.

The pooled results comparing the effect size results of the FE and RE models were presented in forest plot (Figure 2) and the overall effect estimates were also presented in a graph (Supplementary Figure 2). There was variation in glycemic control between countries in children and adolescents during the 10-year study period. The test for heterogeneity between studies was significantly high ($I^2 > 69\%) at almost all of the follow-up time points in the meta-analysis ($\chi^2 P < 0.05$).

Further exploratory sub-group analysis indicates that heterogeneity was consistently high between studies, countries and populations. For the assessment of early glycemic control (low and high HbA1c identified at baseline) and what followed at various time points during the study period, there were four studies with data that could be pooled in the review. The HbA1c levels of the low HbA1c group showed better improvement than the high HbA1c group during the study period. The low and high HbA1c levels at baseline seem to “track” in their respective tracks during the 10-year follow-up however, the initial difference between groups narrows over time (Figure 3).

From the FE meta-analysis, the pooled standardized difference in mean HbA1c levels between patients in the low HbA1c group and those in the high HbA1c group with 95% CI was significant at −1.25 (−1.53, −0.97) after 6 months, −0.85 (−0.95, −0.75) after 1 year, −0.84 (−0.95, −0.74) after 2 years, −0.78 (−0.89, −0.66) after 3 years, −0.44 (−0.54, −0.34) after 5 years, −0.75 (−0.94, −0.55) after 7 years and −0.32 (−0.63, −0.02) after 10 years of T1D diagnosis. The treatment effect in absolute units was a reduction of HbA1c levels on average by 1.6% (range − 0.95 to −2.28%) from baseline, which may be clinically relevant (Table 2).

The study in pre-school aged children (mean age at diagnosis 3.8 ± 1.6 years) showed better control than the other studies with older children.28 The heterogeneity levels were significantly high ($P = 0.001$) at 1, 2, 3, and 5 years after diagnosis and were lower at follow-up time points 0.5, 7, and 10 years after diagnosis ($P > 0.7$) in the meta-analysis.

The meta-analysis was repeated after excluding the study in pre-school aged children (Supplementary Figure 1). The pooled standardized mean difference in HbA1c levels between patients in the low HbA1c group and those in the high HbA1c group with 95% CI was slightly lower at −1.10 (−1.56, −0.65) after 6 months, −0.79 (−0.89, −0.69) after 1 year, −0.78 (−0.89, −0.67) after 2 years, −0.71 (−0.83, −0.59) after 3 years, −0.41 (−0.51, −0.30) after 5 years, −0.72 (−0.92, −0.53) after 7 years and −0.32 (−0.63, −0.02) after 10 years of T1D diagnosis. The treatment effect in absolute units was a reduction of HbA1c levels on an average by 1.49% (range − 0.90 to −2.37%) from baseline. The test for heterogeneity showed improved results and was significantly high only at 5 years after diagnosis ($P = 0.001$) in the meta-analysis (Table 2).

Comparing the long-term HbA1c trajectories between studies revealed that the Israeli study in pre-school children yielded better long-term control (Supplementary Figure 2). Individual study results suggest that early glycemic control tracks during the follow-up in the initially low and high HbA1c groups (Supplementary Figure 3).

Because there were only five studies in the review, we could not assess publication bias using the funnel plot, the Begg adjusted rank correlation test or the Egger test as there was insufficient power to distinguish real asymmetry from random chance.

3.4 | Association of early HbA1c levels and complications risk

Only one longitudinal study24 investigated the association of early glycemic control and future complications and met the inclusion criteria for the systematic review. The study, adjusted for gender, T1D duration, age at diagnosis, physical activity, and smoking; and reported that Swedish children with higher mean HbA1c levels of ≥8.7% (≥70 mmol/mol) 3 to 15 months after diagnosis were significantly more likely to develop macroalbuminuria (OR: 14.3, 95% CI: 2.6-78.2, $P < 0.01$), microalbuminuria (OR: 1.7, 95% CI: 0.8-3.4, $P < 0.05$) and retinopathy (OR: 2.0, 95% CI: 1.2-3.1, $P < 0.01$) in early adulthood (mean age: 21 ± 2.3 years, range: 18-29 years). The study also highlighted the lack of physical activity, smoking, and female gender as predictors of poor glycemic control. However, the role of insulin therapies and other social and family factors on these observations was not reported.

4 | DISCUSSION

We identified five longitudinal studies investigating the impact of early glycemic control on long-term glycemic control in children and adolescents (<19 years) followed from diagnosis of T1D. In the meta-
| Study | Country       | Study_Period | Age_at_diagnosis | N   | ES (95% CI) | % Weight (I-V) |
|-------|---------------|--------------|------------------|-----|-------------|----------------|
| HbA1c at T1D diagnosis |
| Shalitin 2012 | Israel | 1999-2009 | 3.8±1.6 | 173 | 9.85 (9.56, 10.14) | 11.64 |
| Cabrera 2013 | USA | 1998-2002 | 6.8±3.3 | 138 | 9.53 (9.06, 10.00) | 4.44 |
| Clements 2014 | USA | 1993-2009 | 9.0±4.1 | 2218 | 11.00 (11.79, 12.01) | 83.92 |
| I-V Subtotal (I-squared = 99.2%, p = 0.000) |
| D+L Subtotal |
| HbA1c after 3 months of T1D diagnosis |
| Clements 2014 | USA | 1993-2009 | 9.0±4.1 | 2218 | 7.70 (7.62, 7.78) | 91.43 |
| I-V Subtotal (I-squared = 57.8%, p = 0.124) | 7.74 (7.68, 7.80) | 100.00 |
| D+L Subtotal |
| HbA1c after 6 months |
| Shalitin 2012 | Israel | 1999-2009 | 3.8±1.6 | 173 | 7.85 (7.38, 7.71) | 86.42 |
| Lawes 2014 | Scotland, UK | 1993-2012 | 7.8±3.4 | 114 | 8.00 (7.61, 8.39) | 15.58 |
| I-V Subtotal (I-squared = 76.8%, p = 0.038) | 7.61 (7.47, 7.76) | 100.00 |
| D+L Subtotal |
| HbA1c after 1 year |
| Shalitin 2012 | Israel | 1999-2009 | 3.8±1.6 | 173 | 7.70 (7.59, 7.81) | 46.82 |
| Lawes 2014 | Scotland, UK | 1993-2012 | 7.8±3.4 | 114 | 8.15 (7.74, 8.56) | 3.43 |
| Samuelsson 2014 | Sweden | 2000-2010 | 13.9±2.5 | 151 | 7.85 (7.74, 7.96) | 45.76 |
| I-V Subtotal (I-squared = 69.6%, p = 0.037) | 7.79 (7.71, 7.87) | 100.00 |
| D+L Subtotal |
| HbA1c after 2 years |
| Shalitin 2012 | Israel | 1999-2009 | 3.8±1.6 | 140 | 7.70 (7.59, 7.81) | 51.21 |
| Cabrera 2013 | USA | 1998-2002 | 6.8±3.3 | 122 | 8.42 (8.53, 9.05) | 9.09 |
| Lawes 2014 | Scotland, UK | 1993-2012 | 7.8±3.4 | 114 | 8.85 (8.33, 9.38) | 5.44 |
| Samuelsson 2014 | Sweden | 2000-2010 | 13.9±2.5 | 1331 | 7.85 (7.72, 7.98) | 6.47 |
| I-V Subtotal (I-squared = 96.4%, p = 0.000) | 7.90 (7.83, 7.98) | 100.00 |
| D+L Subtotal |
| HbA1c after 3 years |
| Shalitin 2012 | Israel | 1999-2009 | 3.8±1.6 | 116 | 7.75 (7.63, 7.87) | 46.28 |
| Cabrera 2013 | USA | 1998-2002 | 6.8±3.3 | 138 | 8.84 (8.36, 9.24) | 8.84 |
| Clements 2014 | USA | 1993-2009 | 9.0±4.1 | 925 | 9.26 (9.06, 9.32) | 47.01 |
| Samuelsson 2014 | Sweden | 2000-2010 | 13.9±2.5 | 772 | 7.90 (7.77, 8.03) | 40.62 |
| Lawes 2014 | Scotland, UK | 1993-2012 | 7.8±3.4 | 114 | 8.95 (8.56, 9.34) | 4.33 |
| I-V Subtotal (I-squared = 96.0%, p = 0.000) | 7.94 (7.86, 8.03) | 100.00 |
| D+L Subtotal |
| HbA1c after 5 years |
| Shalitin 2012 | Israel | 1999-2009 | 3.8±1.6 | 71 | 7.60 (7.44, 7.76) | 24.26 |
| Cabrera 2013 | USA | 1998-2002 | 6.8±3.3 | 138 | 8.84 (8.36, 9.18) | 5.72 |
| Clements 2014 | USA | 1993-2009 | 9.0±4.1 | 925 | 9.20 (9.06, 9.32) | 47.01 |
| Samuelsson 2014 | Sweden | 2000-2010 | 13.9±2.5 | 772 | 7.80 (7.75, 7.83) | 19.88 |
| Lawes 2014 | Scotland, UK | 1993-2012 | 7.8±3.4 | 80 | 9.25 (8.73, 9.78) | 2.33 |
| I-V Subtotal (I-squared = 96.0%, p = 0.000) | 7.99 (7.86, 8.12) | 100.00 |
| D+L Subtotal |
| HbA1c after 7 years |
| Shalitin 2012 | Israel | 1999-2009 | 3.8±1.6 | 46 | 7.60 (7.41, 7.79) | 50.02 |
| Samuelsson 2014 | Sweden | 2000-2010 | 13.9±2.5 | 465 | 8.20 (8.09, 8.40) | 42.20 |
| Lawes 2014 | Scotland, UK | 1993-2012 | 7.8±3.4 | 58 | 9.30 (8.85, 9.78) | 7.79 |
| I-V Subtotal (I-squared = 96.0%, p = 0.000) | 7.99 (7.86, 8.12) | 100.00 |
| D+L Subtotal |
| HbA1c after 10 years |
| Samuelsson 2014 | Sweden | 2000-2010 | 13.9±2.5 | 193 | 8.65 (8.18, 9.12) | 92.76 |
| Lawes 2014 | Scotland, UK | 1993-2012 | 7.8±3.4 | 25 | 9.10 (7.79, 10.41) | 7.24 |
| I-V Subtotal (I-squared = 0.0%, p = 0.429) | 8.59 (8.24, 8.94) | 100.00 |
| D+L Subtotal |

**FIGURE 2** Summary of fixed effects and random effects models: Pooled estimates of overall glycaemic control at follow-up

FE: fixed effects; RE: random effects; N: number of participants; ES: pooled estimates of HbA1c in absolute units at various time points; I-V: inverse variance; D+L: DerSimonian and Laird
analysis of all included five studies, the overall mean HbA1c levels in all studies were sub-optimal at all follow-up time points. The meta-analysis of the four studies comparing initially low v/s high HbA1c groups, indicates that the low HbA1c group showed overall slightly improved control than the high HbA1c group during the study period. In addition, the meta-analyses suggests that the overall glycemic control was stable in a “track” after 6 months of childhood onset T1D diagnosis. The low and high HbA1c levels at baseline also seem to “track” in their respective tracks during the 10-year follow-up. However, the initial difference between groups narrows over time. The number of participants in the low HbA1c group was small and this may have influenced the power to detect group differences.

Three of the included studies were of intermediate quality while the remaining two were of high quality in reporting potential biases. We adhered to strict systematic review procedures for study selection, data extraction and reporting to minimize reviewer related

### Table 1: HbA1c Levels in Follow-up Studies

| Study | Country | Age at diagnosis | SMD (95% CI) | N, mean (SD); HbA1c <7% | N, mean (SD); HbA1c >7% | % Weight (I-V) | Mean HbA1c |
|-------|---------|------------------|--------------|-------------------------|-------------------------|----------------|-------------|
| Lawes 2014, Scotland, UK | 7.813.4 | HbA1c after 6 months | -1.10 (-1.65, -0.55) | 37, 8.0 (2.1) | 87, 9.2 (2.2) | 37.57 | 8 |
| Shalitlin 2012, Israel | 3.812.5 | -1.25 (-1.63, -0.97) | 207 | 100.00 |
| Lawes 2014, Scotland, UK | 7.813.4 | HbA1c after 1 year | -0.90 (-1.35, -0.45) | 27, 7.1 (2.1) | 87, 9.2 (2.4) | 81.85 |
| Samuelsson 2014, Sweden | 13.812.5 | -0.78 (-0.86, -0.70) | 788, 8.8 (2.4) | 87.89 |
| Shalitlin 2012, Israel | 3.812.5 | -0.85 (-0.95, -0.75) | 963 | 100.00 |
| Lawes 2014, Scotland, UK | 7.813.4 | HbA1c after 2 years | -0.90 (-1.35, -0.45) | 27, 7.1 (2.1) | 87, 9.2 (2.1) | 85.85 |
| Samuelsson 2014, Sweden | 13.812.5 | -0.78 (-0.86, -0.70) | 788, 8.8 (2.4) | 87.89 |
| Shalitlin 2012, Israel | 3.812.5 | -0.85 (-0.95, -0.75) | 963 | 100.00 |
| Lawes 2014, Scotland, UK | 7.813.4 | HbA1c after 3 years | -0.69 (-1.33, -0.25) | 27, 8.2 (2.1) | 87, 9.2 (2.2) | 95.85 |
| Samuelsson 2014, Sweden | 13.812.5 | -0.71 (-0.83, -0.59) | 685, 8.7 (2.4) | 87.89 |
| Shalitlin 2012, Israel | 3.812.5 | -0.81 (-0.99, -0.63) | 79, 6.8 (2.8) | 66.66 |
| Lawes 2014, Scotland, UK | 7.813.4 | HbA1c after 5 years | -0.69 (-1.33, -0.25) | 27, 8.2 (2.1) | 87, 9.2 (2.2) | 95.85 |
| Samuelsson 2014, Sweden | 13.812.5 | -0.71 (-0.83, -0.59) | 685, 8.7 (2.4) | 87.89 |
| Shalitlin 2012, Israel | 3.812.5 | -0.81 (-0.99, -0.63) | 79, 6.8 (2.8) | 66.66 |
| Lawes 2014, Scotland, UK | 7.813.4 | HbA1c after 7 years | -0.49 (-1.07, 0.08) | 17, 8.8 (1.5) | 41, 9.8 (2.2) | 11.67 |
| Samuelsson 2014, Sweden | 13.812.5 | -0.62 (-0.78, -0.47) | 523, 8.9 (2.6) | 43.43 |
| Shalitlin 2012, Israel | 3.812.5 | -1.07 (-1.09, -0.38) | 57, 6.8 (2.8) | 2.33 |
| Lawes 2014, Scotland, UK | 7.813.4 | HbA1c after 10 years | -0.14 (-0.66, 0.38) | 6, 8.9 (3.2) | 19, 9.3 (2.4) | 11.18 |
| Samuelsson 2014, Sweden | 13.812.5 | -0.32 (-0.65, -0.02) | 42, 8.3 (1.9) | 3.35 |
| Shalitlin 2012, Israel | 3.812.5 | -0.32 (-0.65, -0.02) | 42, 8.3 (1.9) | 3.35 |

**FIGURE 3** Summary of fixed effects and random effects models: Estimated standardized mean difference of glycated hemoglobin (HbA1c) levels with 95% confidence interval between the low (exposed to glycaemic control) and high (unexposed to glycaemic control) HbA1c groups during various time-points of follow-up.
| T1D Duration          | Sensitivity MA (after excluding study in pre-school children) | HbA1c % (95% CI) | Heterogeneity (I^2) |
|-----------------------|-------------------------------------------------------------|----------------|--------------------|
| After 6 months of T1D diagnosis | -2.28% (−3.35% to −1.20%) | -1.19% (−1.75% to −0.63%) | 0.0% (p = 0.97) |
| After 1 year of T1D diagnosis     | -1.10% (−1.56% to −0.65%) | 2.37% (3.35% to 1.37%) | 0.0% (p = 0.93) |
| After 2 years of T1D diagnosis     | -0.84% (−1.56% to −0.12%) | 0.0% (p = 0.01) |
| After 3 years of T1D diagnosis     | 0.85% (−0.95% to −0.74%) | 0.0% (p = 0.01) |
| After 5 years of T1D diagnosis     | 0.44% (−0.95% to −0.46%) | 0.0% (p = 0.01) |
| After 10 years of T1D diagnosis    | -0.32% (−0.63% to −0.02%) | 0.0% (p = 0.01) |

Table 2: Summary of pooled standardized mean differences in HbA1c levels between low and high HbA1c groups.

The sub-optimal HbA1c control estimated in the meta-analysis during the follow-up period may be because of more participants with higher HbA1c levels, age, endogenous and exogenous factors or biological variation in the glycation phenotypes of children. Psychological factors particularly in older children are all factors which may also have increased the risk of developing or progression of micro and macrovascular complications in those children as a consequence of those higher HbA1c levels.

The DCCT cohort were able to achieve HbA1c levels of 7% (53 mmol/mol) as compared with 8.3% (66 mmol/mol) achieved among more than 25,000 patients from USA and 8.7% (70.1 mmol/mol) achieved by the pediatric population of England and Wales in the UK. This highlights the fact that, outside of a clinical trial, achieving glycemic targets remains difficult. Hence robustly identifying factors early in the life course of childhood onset T1D that influence future glycemic control and risk of complications remains an important clinical research goal.
strong indicators of a greatly elevated risk for future vascular diseases. There is currently no evidence base for the effectiveness of ACE inhibition or statin treatments in adolescents with T1D although, the important AdDIT Trial may inform practice in the coming years.55 Therefore currently, in order to reduce vascular complications risk, the importance of achieving good glycemic control is arguably greater in childhood compared to adult T1D populations.

The meta-analysis indicates that the overall glycemic control stabilizes in a “track” after 6 months of childhood onset T1D diagnosis and pre-school aged children had better control throughout the follow-up period. Furthermore, the low and high HbA1c levels at baseline also seem to have metabolic memory, which shows HbA1c “tracking” during the 10-year follow-up despite differences between the high and low groups. This suggests there may be benefits of having good control during the initial few months of diagnosis. However, as these five studies report temporal associations, an experimental study of an intervention soon after diagnosis would be required to prove that better early control results in better later control. This review may also indicate a short window of opportunity to intervene and improve long-term glycemic outcomes. It may therefore be beneficial to develop clinical and educational strategies to identify and deliver targeted interventions during this early phase to those at risk of having poor glycemic control and to ensure that the HbA1c targets are maintained in the long-term. There is currently no evidence on effectiveness and timing of focused clinical interventions targeted at changing these tracks.18 It would be useful to gather this evidence and to explore further the mechanisms of this phenomenon in order to deliver best care to newly diagnosed children and adolescents. The findings of this review would be useful to policy makers, health professionals and T1D patients to focus on designing interventions to prevent sub-optimal glycemic outcomes and decrease the risk of developing micro and macro vascular complications.

4.1 | Strengths and limitations of the review

The many strengths of this study include, being to our knowledge, the first systematic review and meta-analysis to rigorously investigate published and unpublished literature on the association of early glycemic control in childhood onset T1D with glycemic tracking and future risk of complications. Furthermore, this is the first review to rigorously and systematically search and review all available evidence as per pre-set inclusion/exclusion and quality assessment criteria. We have taken utmost care to minimize study selection, reviewer related and publication bias. All of the included studies were intermediate to high quality.

But, there are limitations to this systematic review which need to be considered. The diabetes diagnosis, care, and HbA1c outcome measures have evolved over the years and were not uniform across studies. There was considerable heterogeneity between studies. The comparable follow-up data was not available beyond 10 years. We were unable to investigate if other factors may have confounded the findings. The small number of studies and the short duration of follow-up in studies may have masked the true association with long-term glycemic control. Although we made every effort to search for unpublished and gray literature, we may have missed some that remain unreported because of unethical practices in reporting or publication bias. The results of our study may not be generalizable as they were mainly conducted in developed countries with varied health care system models.

4.2 | Review updating plans

The review will be updated if significant new evidence becomes available and results of the update review will be disseminated through peer-reviewed publications, conference presentations and at meetings.

ACKNOWLEDGEMENTS

Our sincere thanks to Dr Mark Clements, Ms Fengming Tang, Dr Ulf Samuelsson, Dr Victoria Franklin and Dr Timothy Lawes—the authors of the included studies who provided us with clarifications and additional information for the review. We also thank the funders and colleagues from University College London especially Dr Rakesh Amin for his initial advice on the project and help with double review of a proportion of included papers. Funding Ref: 109/0001: The Policy Research Unit in the Health of Children, Young People and Families is funded by the Department of Health and Social Care Policy Research Program. This report is independent research commissioned and funded by the National Institute for Health Research Policy Research Program. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research, the Department of Health and Social Care or its arm’s length bodies, and other Government Departments. This research was supported by the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London. Jessica Barrett is funded by the MRC Unit Program (MC_UU_00002/5). David Taylor-Robinson is funded by the MRC on a Clinician Scientist Fellowship (MR/P008577/1).

CONFLICT OF INTEREST

No potential conflict of interest was reported by the authors.

AUTHORS CONTRIBUTION

VMP was the lead reviewer, designed the study, developed the study protocol, created the search strategy, searched electronic databases for literature, extracted the data, co-ordinated with authors of included studies for additional information, analyzed the evidence, drafted the report and is responsible for the article. JB and DTR participated in the study design, contributed to the statistical analysis design and helped revise the manuscript. HC participated in the study design, contributed to the literature search and helped revise the manuscript. DC participated in the study design, contributed to the double review of a proportion of articles and helped revise the manuscript. DD advised on the project, commented on the analyses and helped revise the manuscript. RV advised on the project, participated
in the study design, commented on the analyses and helped revise the manuscript. TS participated in the study design and helped revise the manuscript. All authors contributed to the study design, critical revision of the manuscript and approved the final version.

ORCID

Veena Mazarelo Paes O https://orcid.org/0000-0002-4283-6266
David B. Dunger O https://orcid.org/0000-0002-2566-9304

REFERENCES

1. Hofer SE, Raile K, Frohlich-Reiterer E, et al. Tracking of metabolic control from childhood to young adulthood in type 1 diabetes. J Pediatr. 2014;165(5):956-61.e1-2.

2. Edge JA, James T, Shine B. Persistent individual tracking within overall improvement in HbA1c in a UK paediatric diabetes clinic over 15 years. Diabet Med. 2010;27(11):1284-1288.

3. Chiang JL, Maahs DM, Garvey KC, et al. Type 1 diabetes in children and adolescents: a position statement by the American Diabetes Association. Diabetes Care. 2018;41(9):2026-2044.

4. Speight J, Amiel SA, Bradley C, et al. Long-term biomedical and psychosocial outcomes following DAFNE (dose adjustment for Normal eating) structured education to promote intensive insulin therapy in adults with sub-optimally controlled type 1 diabetes. Diabetes Res Clin Pract. 2010;89(1):22-29.

5. Bronsson AL, Viklund G, Ortvquist E, Lindholm Olinder A. Does treatment with an insulin pump improve glycaemic control in children and adolescents with type 1 diabetes? A retrospective case-control study. Pediatr Diabetes. 2015;16(7):546-553.

6. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The diabetes control and complications trial research group. N Engl J Med. 1993;329(14):977-986.

7. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: diabetes control and complications trial. J Pediatr. 1994;125(2):177-188.

8. Harjutsalo V, Marie-Blikan C, Forsblom C, Groop PH. Impact of sex and age at onset of diabetes on mortality from ischemic heart disease in patients with type 1 diabetes. Diabetes Care. 2014;37(1):144-148.

9. Amiel SA, Shewin RS, Simonson DC, Lauritano AA, Tamborlane WV. Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med. 1986;315(4):215-219.

10. Helgeson VS, Siminerio L, Escobar O, Becker D. Predictors of metabolic control among adolescents with diabetes: a 4-year longitudinal study. J Pediatr Psychol. 2009;34(4):254-270.

11. Wisting L, Froisland DH, Skrivarhaug T, Dahl-Jorgensen K, Ro O. Disturbed eating behavior and omission of insulin in adolescents receiving intensified insulin treatment: a nationwide population-based study. Diabetes Care. 2013;36(11):3382-3387.

12. Meigs JB, Nathan DM, Cupples LA, Wilson PWF, Singer DE. Tracking of glycated hemoglobin in the original cohort of the Framingham heart study. J Clin Epidemiol. 1996;49(4):411-417.

13. Hammar RF, Bell RA, Dabelea D, et al. The SEARCH for diabetes in youth study: rationale, findings, and future directions. Diabetes Care. 2014;37(12):3336-3344.

14. Rosenbauer J, Dost A, Karges B, et al. Improved metabolic control in children and adolescents with type 1 diabetes: a trend analysis using prospective multicenter data from Germany and Austria. Diabetes Care. 2012;35(1):80-86.

15. Dovc K, Telic SS, Luna L, et al. Improved metabolic control in pediatric patients with type 1 diabetes: a nationwide prospective 12-year time trends analysis. Diabetes Technol Ther. 2014;16(1):33-40.

16. Nathan DM, Turgeon H, Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia. 2007;50(11):2239-2244.

17. Svensson M, Eriksson JW, Dahlquist G. Early glycaemic control, age at onset, and development of microvascular complications in childhood-onset type 1 diabetes: a population-based study in northern Sweden. Diabetes Care. 2004;27(4):955-962.

18. Nirantarakhumar K, Mohammed N, Toulis KA, Thomas GN, Narendran P. Clinically meaningful and lasting HbA1c improvement rarely occurs after 5 years of type 1 diabetes: an argument for early, targeted and aggressive intervention following diagnosis. Diabetologia. 2018;61(5):1064-1070.

19. Mazarelo Paes V, Charalampopoulos D, Kanolikar AR, et al. Protocol for systematic review of evidence on the determinants and influence of early glycaemic control in childhood-onset type 1 diabetes. Syst Rev. 2015;4(1):159.

20. EPPI. Evidence for Policy and Practice Information (EPPI) and Coordinating Centre, IoE, University of London EPPI -Centre Methods for Conducting Systematic Reviews http://epiioe.ac.uk/cms/Default.aspx?tabid=184 last accessed September 15, 2018. 2018.

21. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.

22. Watson PF, Petrie A. Method agreement analysis: a review of correct methodology. Theriogenology. 2010;73(9):1167-1179.

23. Higgins JP, Green S, eds. Cochrane Handbook for Systematic Review of Interventions. Chichester: Wiley-Blackwell; 2008.

24. Samuelsson U, Steineck I, Gubbjornsdottir S. A high mean-HbA1c value 3-15 months after diagnosis of type 1 diabetes in childhood is related to metabolic control, macroalbuminuria, and retinopathy in early adulthood--a pilot study using two nation-wide population based quality registries. Pediatr Diabetes. 2014;15(3):229-235.

25. Sutton AJ, Higgins JPT. Recent developments in meta-analysis. Stat Med. 2008;27(5):625-650.

26. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558.

27. Lawes T, Franklin V, Farmer G. HbA1c tracking and bio-psychosocial determinants of glycaemic control in children and adolescents with type 1 diabetes: retrospective cohort study and multilevel analysis. Pediatr Diabetes. 2014;15(5):372-383.

28. Shallah S, Phillip M. Which factors predict glycemic control in children diagnosed with type 1 diabetes before 6.5 years of age? Acta Diabetol. 2012;49(5):355-362.

29. Clements MA, Lind M, Raman S, et al. Age at diagnosis predicts deterioration in glycaemic control among children and adolescents with type 1 diabetes. BMJ Open Diabetes Res Care. 2014;2(1):e000039.

30. Cabrera SM, Srivastava NT, Behzadi JM, Potterff TM, Dimeglio LA, Walvoord EC. Long-term glycaemic control as a result of initial education for children with new onset type 1 diabetes: does the setting matter? Diabetes Educ. 2013;39(2):187-194.

31. de Beaufort CE, Swift PGF, Skinner CT, et al. Continuing stability of center differences in pediatric diabetes care: do advances in diabetes treatment improve outcome? The Hvidoere study group on childhood diabetes. Diabetes Care. 2007;30(9):2245-2250.

32. Svensson J, Johannesson J, Mortensen HB, Nordy S, On behalf of The Danish Childhood Diabetes Registry. Improved metabolic outcome in a Danish diabetic paediatric population aged 0-18 yr: results from a nationwide continuous registration. Pediatr Diabetes. 2009;10(7):461-467.
33. Dabadghao P, Vidmar S, Cameron FJ. Deteriorating diabetic control through adolescence-do the origins lie in childhood? Diabet Med. 2001;18(11):889-894.

34. Yukin JS, Forrest RD, Jackson CA, Ryle AJ, Davie S, Gould BJ. Unexplained variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia. Diabetologia. 1990;33(4):208-215.

35. Kilpatrick ES, Rigby AS, Atkin SL. Variability in the relationship between mean plasma glucose and HbA1c: implications for the assessment of glycemic control. Clin Chem. 2007;53(5):897-901.

36. Hempe JM, Gomez R, McCarter RJ Jr, Chalew SA. High and low hemoglobin glycation phenotypes in type 1 diabetes: a challenge for interpretation of glycemic control. J Diabetes Complications. 2002;16(5):313-320.

37. Luyckx K, Seiffge-Krenke I. Continuity and change in glycemic control trajectories from adolescence to emerging adulthood: relationships with family climate and self-concept in type 1 diabetes. Diabetes Care. 2009;32(5):797-801.

38. Bryden KS, Dunger DB, Mayou RA, Peveler RC, Neil HAW. Poor prognosis of young adults with type 1 diabetes: a longitudinal study. Diabetes Care. 2003;26(4):1052-1057.

39. Nathan DM, Bayless M, Cleary P, et al. Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. Diabetes. 2013;62(12):3976-3986.

40. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med. 2013;368(17):1613-1624.

41. Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA. The T1D exchange clinic registry. J Clin Endocrinol Metab. 2012;97(12):4383-4389.

42. RCPCH. National Paediatric Diabetes Audit Report 2014-15. Care processes and outcomes 2016. Available from: http://www.rcpch.ac.uk/sites/default/files/page/NPDA%20Report%202014-15%20v5.2%20sent%20to%20HQIP%2025.05.2016.pdf.

43. Olsen BS, Spolie AK, Hougaard P, et al. The significance of the prepubertal diabetes duration for the development of retinopathy and nephropathy in patients with type 1 diabetes. J Diabetes Complications. 2004;18(3):160-164.

44. Fredheim S, Johannesen J, Johansen A, et al. Diabetic ketoacidosis at the onset of type 1 diabetes is associated with future HbA1c levels. Diabetologia. 2013;56(5):995-1003.

45. Larsen J, Brekke M, Sandvik L, Arnesen H, Hanssen KF, Dahl-Jorgensen K. Silent coronary atheromatosis in type 1 diabetic patients and its relation to long-term glycemic control. Diabetes. 2002;51(8):2637-2641.

46. Dabelea D, Kinney G, Snell-Begeon JK, et al. Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The coronary artery calcification in type 1 diabetes (CACTI) study. Diabetes. 2003;52(11):2833-2839.

47. Herrett E, Shah AD, Boggon R, et al. Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study. BMJ. Clin Res Ed. 2013;346:f2350.

48. Pajunen P, Taskinen MR, Nieminen MS, Syvanne M. Angiographic severity and extent of coronary artery disease in patients with type 1 diabetes mellitus. Am J Cardiol. 2000;86(10):1080-1085.

49. Nathan DM, Lachin J, Cleary P, et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 2003;348(23):2294-2303.

50. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-2653.

51. Dahl-Jorgensen K, Larsen JR, Hanssen KF. Atherosclerosis in childhood and adolescent type 1 diabetes: early disease, early treatment? Diabetologia. 2005;48(8):1445-1453.

52. Giannattasio C, Failla M, Piperno A, et al. Early impairment of large artery structure and function in type 1 diabetes mellitus. Diabetologia. 1999;42(8):987-994.

53. Schwab KO, Doerfer J, Hecker W, et al. Spectrum and prevalence of atherogenic risk factors in 27,358 children, adolescents, and young adults with type 1 diabetes: cross-sectional data from the German diabetes documentation and quality management system (DPV), Diabetes Care. 2006;29(2):218-225.

54. Amin R, Frystyk J, Ong K, Dalton RN, Flyvbjerg A, Dunger DB. The development of microalbuminuria is associated with raised longitudinal adiponectin levels in female but not male adolescent patients with type 1 diabetes. Diabetologia. 2008;51(9):1707-1713.

55. Adolescent type 1 Diabetes Cardio-renal Intervention Trial (ADDITION-CACTI) study. BMJ. 2009 Dec 17;9:79. https://doi.org/10.1186/1471-2431-9-79.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.